



(51) International Patent Classification:

A61K 35/17 (2015.01) C12N 5/071 (2010.01)
A61K 35/36 (2015.01) C12N 5/0783 (2010.01)
A61K 35/39 (2015.01) A61K 35/30 (2015.01)
A61K 35/44 (2015.01) C12N 5/079 (2010.01)
A61K 35/55 (2015.01) C12N 15/113 (2010.01)
A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2022/074878

(22) International Filing Date:

11 August 2022 (11.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/232,161	11 August 2021 (11.08.2021)	US
63/297,694	07 January 2022 (07.01.2022)	US
63/344,502	20 May 2022 (20.05.2022)	US
63/348,990	03 June 2022 (03.06.2022)	US
63/353,531	17 June 2022 (17.06.2022)	US

(71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US];
188 East Blaine Street, Suite 400, Seattle, Washington
98102 (US).

(72) Inventors: HU, Xiaomeng; c/o Sana Biotechnology, Inc.,
188 East Blaine Street, Suite 400, Seattle, Washington
98102 (US). SCHREPFER, Sonja; c/o Sana Biotechnolo-
gy, Inc., 188 East Blaine Street, Suite 400, Seattle, Wash-
ington 98102 (US).

(74) Agent: BRADLEY, Michelle Celine et al.; Morrison & Fo-
rster LLP, 755 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY




FIG. 1

(57) Abstract: Provided are engineered cells, such as engineered primary cells, containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered primary cells are hypimmunogenic cells.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*